Showing results (41-50 of 1,822) with videos related to
Sort By:
Pageof 183
Biological Psychiatry|February 1, 1982
Ex uno multi: subtyping the schizophrenic syndromeD V Jeste, J E Kleinman, S G Potkin, et al.Molecular Psychiatry|January 31, 2003
D1 receptor alleles predict PET metabolic correlates of clinical response to clozapineS G Potkin, V S Basile, Y Jin, et al.European Journal of Pharmacology|October 31, 1996
Decrease in sigma but no increase in striatal dopamine D4 sites in schizophrenic brainsD M Helmeste, S W Tang, W E Bunney, et al.Psychopharmacology|June 13, 2001
Intramuscular (IM) ziprasidone 20 mg is effective in reducing acute agitation associated with psychosis: a double-blind, randomized trialD G Daniel, S G Potkin, K R Reeves, et al.Schizophrenia Bulletin|January 1, 1980
Monoamine oxidase in schizophrenia: an overviewR J Wyatt, S G Potkin, T P Bridge, et al.Archives of General Psychiatry|March 1, 1993
Distorted distribution of nicotinamide-adenine dinucleotide phosphate-diaphorase neurons in temporal lobe of schizophrenics implies anomalous cortical developmentS Akbarian, A Viñuela, J J Kim, et al.Archives of General Psychiatry|July 1, 1983
Plasma phenylalanine, tyrosine, and tryptophan in schizophreniaS G Potkin, H E Cannon-Spoor, L E DeLisi, et al.Archives of General Psychiatry|May 1, 1996
Maldistribution of interstitial neurons in prefrontal white matter of the brains of schizophrenic patientsS Akbarian, J J Kim, S G Potkin, et al.Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology|April 8, 1999
Ziprasidone 80 mg/day and 160 mg/day in the acute exacerbation of schizophrenia and schizoaffective disorder: a 6-week placebo-controlled trial. Ziprasidone Study GroupD G Daniel, D L Zimbroff, S G Potkin, et al.Science (New York, N.Y.)|October 26, 1979
Phenylethylamine in paranoid chronic schizophreniaS G Potkin, F Karoum, L W Chuang, et al.Pageof 183